Clinical trial MCLA-128-CL02
Phase 2 study of MCLA-128-CL02 Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Merus |
| EudraCT Identifier | 2017-002821-39 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03321981 |
| Inclusion criteria | 3rd to 5th line, FISH+ (IHC ++/+++), prior trastu/pertu &TDM1 |
| Last update |